Systemic inflammation and proinflammatory interleukin-17 signalling persist at the end of therapy in patients with metabolic syndrome and psoriasis, reducing the length of remission

Coimbra, S. ; Oliveira, H. ; Neuparth, M.J. ; Proença, J.B. ; Figueiredo, A. ; Rocha-Pereira, P. ; Santos-Silva, A.

British journal of dermatology (1951), 2016-02, Vol.174 (2), p.414-416 [Periódico revisado por pares]

England: Blackwell Publishing Ltd

Texto completo disponível